// App-Quantinova.ai

11532 : Bleeding Likelihood of Apixaban in Primary VTE Prophylaxis: A Meta-Analysis

Researchers

Presenter

  • Harsh Golwala

Principal Investigators

  • Angeline Opina

  • Alfonso Tafur

Medical Centers

  • University of Oklahoma Health Sciences Center, Oklahoma City, OK

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Pulmonary embolism

Biomarkers

  • N/A

Drug/Treatment

  • Enoxaparin

  • Enoxaparin sodium

  • apixaban

  • Heparin

Outcome

  • N/A

Study Design

  • superiority

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved